A groundbreaking new book, reviewed this week in Nature, reveals how a quiet revolution in clinical trials transformed global health policy—shifting medicine from tradition and authority to data-driven science. The meticulously researched account traces the rise of evidence-based medicine (EBM) and the often-overlooked figures who fought to make rigorous testing the foundation of modern healthcare. Their struggle, the book argues, was not just scientific but political, challenging entrenched power structures in medicine, pharmaceuticals, and public health.
What Happened: The Rise of Evidence-Based Medicine
The book details how randomized controlled trials (RCTs), first developed in the 1940s, became the gold standard for medical decision-making only decades later. A pivotal moment came in 1992 with the founding of the Cochrane Collaboration, an international nonprofit that synthesizes clinical trial data to produce unbiased reviews of medical interventions. By the 2010s, Cochrane’s work had become indispensable for policymakers, forcing governments and insurers to justify coverage decisions with hard evidence rather than expert opinion alone.
The impact has been far-reaching. In the United States, the 2010 Affordable Care Act tied Medicare reimbursements to evidence-based guidelines, reducing spending on ineffective treatments. In the United Kingdom, the National Institute for Health and Care Excellence (NICE) used RCT data to deny coverage for drugs deemed insufficiently beneficial, sparking debates but saving billions in public funds. Even in low- and middle-income countries, EBM has helped prioritize cost-effective interventions—such as childhood vaccines and HIV antiretrovirals—over expensive, unproven therapies.
Why It Matters: A Shift in Medical Authority
The book’s central argument is that EBM did not emerge by accident—it was the result of a deliberate campaign by “mavericks” who challenged medical elites. Figures like epidemiologist Sir Iain Chalmers, a co-founder of the Cochrane Collaboration, and physician David Sackett, who popularized the term “evidence-based medicine” in the 1990s, pushed for a culture of skepticism and transparency. Their work, the book contends, was as much a political battle as a scientific one, dismantling the idea that medical authority should go unquestioned.
Yet the movement’s success has not been without controversy. Critics argue that EBM’s rigid adherence to trial data can stifle innovation or overlook patient-specific factors. Others point to persistent gaps in evidence, particularly for rare diseases or treatments where large-scale trials are impractical. The Nature review also highlights concerns about industry influence, noting that pharmaceutical companies now fund the majority of clinical trials—a dynamic that has led to accusations of selective data reporting and conflicts of interest.
Background and Context: From Anecdote to Evidence
For centuries, medical practice relied on anecdote, tradition, or the authority of senior physicians. Treatments were often prescribed based on personal experience rather than rigorous testing. The shift toward EBM began in the mid-20th century, accelerated by scandals like the thalidomide tragedy, which exposed the dangers of untested drugs. By the 1990s, the Cochrane Collaboration and other initiatives formalized the use of systematic reviews, ensuring that medical decisions were grounded in the best available evidence.
The book also examines how EBM reshaped public policy. Governments and insurers increasingly demanded proof of efficacy before approving treatments, leading to more efficient healthcare spending. However, the movement’s reliance on RCTs has also been criticized for favoring interventions that are easier to study—such as drugs—over complex, long-term therapies like behavioral interventions or public health programs.
Competing Claims and Uncertainty
While EBM has undeniably improved medical outcomes, its limitations remain a subject of debate. Some clinicians argue that an overemphasis on trial data can ignore individual patient needs, particularly in cases where evidence is scarce. Others warn that industry-funded trials may skew results in favor of profitable treatments, undermining the movement’s original ideals of independence and transparency.
The book also raises questions about the future of EBM. As medicine advances into fields like AI-driven diagnostics and gene therapy, the pressure to act quickly often outpaces the ability to generate robust evidence. Will the principles of EBM adapt, or will new forms of medical authority emerge?
What to Watch Next: The Future of Evidence-Based Medicine
The book suggests that today’s “mavericks” may no longer be found in academia or medicine but in patient advocacy groups, open-science collectives, and regulatory agencies pushing for greater transparency. Their fight, it argues, is far from over.
Key developments to monitor include:
– Regulatory reforms to address industry influence in clinical trials.
– Expansion of EBM into new fields like digital health and personalized medicine.
– Debates over evidence gaps, particularly for rare diseases and emerging therapies.
Conclusion: A Revolution Still Unfolding
The rise of evidence-based medicine marks one of the most significant shifts in medical history—a move from deference to authority to reliance on verifiable data. Yet the book’s account also serves as a cautionary tale. The same forces that once resisted EBM—pharmaceutical profits, medical tradition, regulatory inertia—have adapted, finding new ways to shape the evidence landscape.
For policymakers and patients alike, the lesson is clear: evidence alone is not enough. Without mechanisms to ensure trial integrity, public access to data, and independent oversight, even the most rigorous science can be co-opted. As medicine continues to evolve, the battle for evidence over dogma remains as relevant as ever.
Story synopsis gathered from: [Nature](https://www.nature.com/articles/d41586-026-02153-9) — source.
Corrections
If you believe this article contains an error, contact Herald Express with the source URL and supporting evidence.
Story synopsis gathered from: Nature — source.
